Date: 2013-05-23
Type of information: Collaboration agreement
Compound: drug safety tests
Company: IMI (EU) Critical Path Institute (USA)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 23, 2013, the Predictive Safety Testing Consortium (PSTC) led by the Critical Path Institute (C-Path) and the Safer and Faster Evidence-based Translation (SAFE-T) consortium sponsored by the Innovative Medicines Initiatives (IMI) have signed an agreement to work together in their efforts to improve drug safety. Both PSTC and SAFE-T are working on the development of new biomarkers to improve our ability to predict, diagnose and monitor drug-induced injury to the liver, kidney and vascular system. Both consortium intend to qualify biomarkers that are more specific, more sensitive and more predictive than the currently available biomarkers and to gain regulatory acceptance for routine use of these biomarkers in preclinical and clinical drug development.
Financial terms:
Latest news:
